Literature DB >> 21707579

Lymphomas in sub-Saharan Africa--what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research?

Kikkeri N Naresh1, Martine Raphael, Leona Ayers, Nina Hurwitz, Valeria Calbi, Emily Rogena, Shahin Sayed, Omar Sherman, Hazem A H Ibrahim, Stefano Lazzi, Vasileios Mourmouras, Patricia Rince, Jessie Githanga, Bessie Byakika, Emma Moshi, Muheez Durosinmi, Babatunde J Olasode, Olayiwola A Oluwasola, Effiong E Akang, Yetunde Akenòva, Melissa Adde, Ian Magrath, Lorenzo Leoncini.   

Abstract

Approximately 30 000 cases of non-Hodgkin lymphoma (NHL) occur in the equatorial belt of Africa each year. Apart from the fact that Burkitt lymphoma (BL) is very common among children and adolescents in Africa and that an epidemic of human immunodeficiency virus (HIV) infection is currently ongoing in this part of the world, very little is known about lymphomas in Africa. This review provides information regarding the current infrastructure for diagnostics in sub-Saharan Africa. The results on the diagnostic accuracy and on the distribution of different lymphoma subsets in sub-Saharan Africa were based on a review undertaken by a team of lymphoma experts on 159 fine needle aspirate samples and 467 histological samples during their visit to selected sub-Saharan African centres is presented. Among children (<18 years of age), BL accounted for 82% of all NHL, and among adults, diffuse large B-cell lymphoma accounted for 55% of all NHLs. Among adults, various lymphomas other than BL, including T-cell lymphomas, were encountered. The review also discusses the current strategies of the International Network of Cancer Treatment and Research on improving the diagnostic standards and management of lymphoma patients and in acquiring reliable clinical and pathology data in sub-Saharan Africa for fostering high-quality translational research.
© 2011 Blackwell Publishing Ltd.

Entities:  

Keywords:  epidemiology; lymphomas; malignant haematology

Mesh:

Year:  2011        PMID: 21707579      PMCID: PMC4207091          DOI: 10.1111/j.1365-2141.2011.08772.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.

Authors:  E Leucci; M Cocco; A Onnis; G De Falco; P van Cleef; C Bellan; A van Rijk; J Nyagol; B Byakika; S Lazzi; P Tosi; H van Krieken; L Leoncini
Journal:  J Pathol       Date:  2008-12       Impact factor: 7.996

2.  Accuracy of Burkitt lymphoma diagnosis in constrained pathology settings: importance to epidemiology.

Authors:  Martin D Ogwang; Weiqiang Zhao; Leona W Ayers; Sam M Mbulaiteye
Journal:  Arch Pathol Lab Med       Date:  2011-04       Impact factor: 5.534

3.  Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes.

Authors:  Pier Paolo Piccaluga; Giulia De Falco; Manjunath Kustagi; Anna Gazzola; Claudio Agostinelli; Claudio Tripodo; Eleonora Leucci; Anna Onnis; Annalisa Astolfi; Maria Rosaria Sapienza; Cristiana Bellan; Stefano Lazzi; Lynnette Tumwine; Michael Mawanda; Martin Ogwang; Valeria Calbi; Serena Formica; Andrea Califano; Stefano A Pileri; Lorenzo Leoncini
Journal:  Blood       Date:  2011-01-18       Impact factor: 22.113

4.  High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.

Authors:  Albert Oriol; Josep-Maria Ribera; Juan Bergua; Eduardo Giménez Mesa; Carlos Grande; Jordi Esteve; Salut Brunet; Maria-Jose Moreno; Lourdes Escoda; Jesus-Maria Hernandez-Rivas; Dieter Hoelzer
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

5.  Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.

Authors:  Anna Onnis; Giulia De Falco; Giuseppina Antonicelli; Monica Onorati; Cristiana Bellan; Omar Sherman; Shaheen Sayed; Lorenzo Leoncini
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

Review 6.  Lessons from clinical trials in African Burkitt lymphoma.

Authors:  Ian Magrath
Journal:  Curr Opin Oncol       Date:  2009-09       Impact factor: 3.645

7.  Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors.

Authors:  Giulia De Falco; Eleonora Leucci; Dido Lenze; Pier Paolo Piccaluga; Pier Paolo Claudio; Anna Onnis; Giovanna Cerino; Joshua Nyagol; Walter Mwanda; Cristiana Bellan; Michael Hummel; Stefano Pileri; Piero Tosi; Harald Stein; Antonio Giordano; Lorenzo Leoncini
Journal:  Blood       Date:  2007-05-07       Impact factor: 22.113

8.  B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.

Authors:  Eleonora Leucci; Anna Onnis; Mario Cocco; Giulia De Falco; Francesco Imperatore; Antonicelli Giuseppina; Valentina Costanzo; Giovanna Cerino; Susanna Mannucci; Rocco Cantisani; Joshua Nyagol; Walter Mwanda; Robert Iriso; Martin Owang; Karin Schurfeld; Cristiana Bellan; Stefano Lazzi; Lorenzo Leoncini
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

9.  Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials.

Authors:  Wolfram Klapper; Monika Szczepanowski; Birgit Burkhardt; Hilmar Berger; Maciej Rosolowski; Stefan Bentink; Carsten Schwaenen; Swen Wessendorf; Rainer Spang; Peter Möller; Martin Leo Hansmann; Heinz-Wolfram Bernd; German Ott; Michael Hummel; Harald Stein; Markus Loeffler; Lorenz Trümper; Martin Zimmermann; Alfred Reiter; Reiner Siebert
Journal:  Blood       Date:  2008-05-28       Impact factor: 22.113

10.  Malignant lymphomas (ML) and HIV infection in Tanzania.

Authors:  Amos R Mwakigonja; Ephata E Kaaya; Edward M Mgaya
Journal:  J Exp Clin Cancer Res       Date:  2008-06-10
View more
  38 in total

1.  Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi.

Authors:  Katherine D Westmoreland; Nathan D Montgomery; Christopher C Stanley; Nader Kim El-Mallawany; Peter Wasswa; Toon van der Gronde; Idah Mtete; Mercy Butia; Salama Itimu; Mary Chasela; Mary Mtunda; Coxcilly Kampani; N George Liomba; Tamiwe Tomoka; Bal M Dhungel; Marcia K Sanders; Robert Krysiak; Peter Kazembe; Dirk P Dittmer; Yuri Fedoriw; Satish Gopal
Journal:  Int J Cancer       Date:  2017-03-24       Impact factor: 7.396

2.  Celebrating treatment completion in sub-Saharan Africa.

Authors:  Meaghann Shaw Weaver
Journal:  Nat Rev Clin Oncol       Date:  2013-12-17       Impact factor: 66.675

3.  Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities.

Authors:  Elizabeth A Morgan; M Patrick Sweeney; Tamiwe Tomoka; Nadja Kopp; Daniel Gusenleitner; Robert A Redd; Christopher D Carey; Leo Masamba; Steve Kamiza; Geraldine S Pinkus; Donna S Neuberg; Scott J Rodig; Danny A Milner; David M Weinstock
Journal:  Blood Adv       Date:  2016-11-22

4.  Accurate Real-Time Diagnosis of Lymphoproliferative Disorders in Malawi Through Clinicopathologic Teleconferences:  A Model for Pathology Services in Sub-Saharan Africa.

Authors:  Nathan D Montgomery; N George Liomba; Coxcilly Kampani; Robert Krysiak; Christopher C Stanley; Tamiwe Tomoka; Steve Kamiza; Bal M Dhungel; Satish Gopal; Yuri Fedoriw
Journal:  Am J Clin Pathol       Date:  2016-09-04       Impact factor: 2.493

Review 5.  Meeting the challenge of hematologic malignancies in sub-Saharan Africa.

Authors:  Satish Gopal; William A Wood; Stephanie J Lee; Thomas C Shea; Kikkeri N Naresh; Peter N Kazembe; Corey Casper; Peter B Hesseling; Ronald T Mitsuyasu
Journal:  Blood       Date:  2012-03-28       Impact factor: 22.113

6.  EBV-Positive Grey Zone Lymphoma in an HIV Infected Man from Kampala, Uganda: Case Report.

Authors:  Lynette K Tumwine; Jackson Orem; Leona W Ayers
Journal:  Int J Med Pharm Case Reports       Date:  2014-11-15

7.  Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort.

Authors:  Matthew S Painschab; Edwards Kasonkanji; Takondwa Zuze; Bongani Kaimila; Tamiwe Tomoka; Richard Nyasosela; Ruth Nyirenda; Bal M Dhungel; Maurice Mulenga; Maria Chikasema; Blessings Tewete; Asekanadziwa Mtangwanika; Sarah Chiyoyola; Wilberforce Mhango; Fred Chimzimu; Coxcilly Kampani; Robert Krysiak; Thomas C Shea; Nathan D Montgomery; Yuri Fedoriw; Satish Gopal
Journal:  Br J Haematol       Date:  2018-11-18       Impact factor: 6.998

8.  Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease.

Authors:  Twalib Ngoma; Melissa Adde; Muheez Durosinmi; Jessie Githang'a; Yetunde Aken'Ova; Jane Kaijage; Oluwagbemiga Adeodou; Jamilla Rajab; Biobele J Brown; Lorenzo Leoncini; Kikkeri Naresh; Martine Raphael; Nina Hurwitz; Patricia Scanlan; Ama Rohatiner; David Venzon; Ian Magrath
Journal:  Br J Haematol       Date:  2012-07-30       Impact factor: 6.998

Review 9.  How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa.

Authors:  Satish Gopal; Thomas G Gross
Journal:  Blood       Date:  2018-05-16       Impact factor: 22.113

10.  Multicentric Castleman's disease in Malawi.

Authors:  Satish Gopal; Yuri Fedoriw; Nathan D Montgomery; Coxcilly Kampani; Robert Krysiak; Marcia K Sanders; Dirk P Dittmer; N George Liomba
Journal:  Lancet       Date:  2014-09-20       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.